arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ImageneBio, Inc.

IMA
$4.08 ▲ +0.04 (+1.11%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Bearish
auto_awesome

Analytical Summary

ImageneBio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -8.3% ↗
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-10.62M
↓ -23.2% —
Operating Margin Operating profit as % of sales
-58.2%
↑ +80.1% —
FCF / Share Free cash flow per share
$-1.32
↓ -503.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
21
Cash Quality ↓
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters